Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Rejlers AB Class B ( ($SE:REJL.B) ) has provided an announcement.
Rejlers has been appointed engineering partner for a major upgrade of Fermion’s pharmaceutical production facility in Hanko, Finland, transforming an idle unit into a modern plant that meets current pharmaceutical manufacturing standards. The contract underscores Rejlers’ role in high-spec industrial projects, as it will deliver process, piping, layout, electrical and structural engineering in line with stringent safety and regulatory frameworks such as HAZOP and ATEX.
The project, which began its engineering phase in early 2026 and is due to conclude by year-end, will significantly expand Fermion’s capacity to produce active pharmaceutical ingredients, particularly for prostate cancer treatments. By boosting output at a key site supplying APIs to Orion Corporation and international drugmakers, the upgrade strengthens Fermion’s position in the global pharmaceutical supply chain while highlighting Rejlers’ ability to manage complex, multi-stakeholder assignments in regulated industries.
More about Rejlers AB Class B
Rejlers is a leading Nordic engineering consultancy operating in Sweden, Finland, Norway and the United Arab Emirates, with 3,400 experts serving the energy, industry, buildings, infrastructure and defence sectors. The company focuses on acting as a catalyst for sustainable transformation for its clients, and its class B share is listed on the Nasdaq Stockholm Mid Cap market.
YTD Price Performance: -16.77%
Average Trading Volume: 42,415
Technical Sentiment Signal: Hold
Current Market Cap: SEK3.6B
See more insights into REJL.B stock on TipRanks’ Stock Analysis page.